Initial Experience With Nifekalant Hydrochloride (MS-551), A Novel Class III Antiarrhythmic Agent, in Patients With Acute Extensive Infarction and Severe Ventricular Dysfunction

Abstract

Nifekalant hydrocholoride, a novel class III antiarrhythmic agent, was used as the treatment in 4 patients with extensive anterior infarction and severe ventricular dysfunction. The malignant ventricular tachyarrhythmia was effectively suppressed at a relatively low dose, without compromising the hemodynamics, indicating that this potent K⁺ channel blocker has therapeutic potential for acute myocardial infarction. (Jpn Circ J 2001; 65: 60 - 62)